Last reviewed · How we verify
Aspirin + Clopidogrel + Rivaroxaban
This triple anticoagulant/antiplatelet combination inhibits blood clotting through multiple pathways: aspirin and clopidogrel block platelet aggregation, while rivaroxaban inhibits Factor Xa in the coagulation cascade.
This triple anticoagulant/antiplatelet combination inhibits blood clotting through multiple pathways: aspirin and clopidogrel block platelet aggregation, while rivaroxaban inhibits Factor Xa in the coagulation cascade. Used for Acute coronary syndrome with high thrombotic risk, Secondary prevention of cardiovascular events in post-acute coronary syndrome patients.
At a glance
| Generic name | Aspirin + Clopidogrel + Rivaroxaban |
|---|---|
| Also known as | Triple Antithrombotic Therapy |
| Sponsor | China National Center for Cardiovascular Diseases |
| Drug class | Antiplatelet agent + Anticoagulant combination |
| Target | Platelet cyclooxygenase, P2Y12 receptor, Factor Xa |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Aspirin irreversibly inhibits cyclooxygenase to prevent thromboxane A2 production, clopidogrel blocks P2Y12 adenosine diphosphate receptors on platelets, and rivaroxaban is a direct Factor Xa inhibitor that prevents thrombin generation. Together, these agents provide dual antiplatelet therapy combined with anticoagulation for enhanced thromboprophylaxis in high-risk cardiovascular patients.
Approved indications
- Acute coronary syndrome with high thrombotic risk
- Secondary prevention of cardiovascular events in post-acute coronary syndrome patients
Common side effects
- Bleeding (major and minor)
- Gastrointestinal bleeding
- Intracranial hemorrhage
- Dyspepsia
- Anemia
Key clinical trials
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
- PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years (PHASE3)
- Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis (PHASE3)
- STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for Oral Anticoagulant (PHASE4)
- Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.
- Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG (PHASE3)
- Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy (PHASE4)
- Rivaroxaban for Slow Coronary Flow After PCI in STEMI (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: